Malt Lymphoma Pipeline | Companies – MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology, and Others
DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Malt Lymphoma pipeline, providing valuable insights into emerging therapies and companies.
DelveInsight’s, “Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape. It covers the Malt Lymphoma pipeline drug profiles, including Malt Lymphoma clinical trials and nonclinical stage products. It also covers the Malt Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Malt Lymphoma Pipeline treatment landscape of the report, click here @ Malt Lymphoma Pipeline Outlook
Key Takeaways from the Malt Lymphoma Pipeline Report
- DelveInsight’s Malt Lymphoma Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Malt Lymphoma.
- The leading Malt Lymphoma Companies include MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology, and Others.
- Promising Malt Lymphoma Pipeline Therapies include Zanubrutinib, Lenalidomide, Obinutuzumab, tafasitamab, Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide, Fentanyl sublingual spray, Fragmin, and others
- MALT lymphomas do not have a specific antigenic profile, the B-cells sharing the immunophenotype with marginal zone B-cells present in the spleen, Peyer’s patches and lymph nodes, so gastric lymphoma is CD20+, CD5+; CD10-, CD23- and cyclin D1..
- The Malt Lymphoma companies and academics are working to assess challenges and seek opportunities that could influence in Malt Lymphoma R&D. The Malt Lymphoma therapies under development are focused on novel approaches to treat/improve in Malt Lymphoma.
For further information, refer to the detailed Malt Lymphoma Unmet Needs, Malt Lymphoma Market Drivers, and Malt Lymphoma Market Barriers, click here for Malt Lymphoma Ongoing Clinical Trial Analysis
Malt Lymphoma Overview
The neoplastic proliferation of B cells in the marginal zone of lymphoid tissue gives rise to marginal zone B cell lymphomas. Mucosa-associated lymphoid tissue lymphoma or MALT lymphoma is the term used for extranodal marginal zone lymphoma referred to as MALT Lymphoma. Other commonly involved extranodal sites include other parts of the gastrointestinal tract, thyroid, salivary gland, lung, lacrimal gland, synovium, dura mater, skin, and eyes.
Request a sample and discover the recent advances in Malt Lymphoma Ongoing Clinical Trial Analysis and Medications, click here @ Malt Lymphoma Treatment Landscape
Malt Lymphoma Emerging Drugs Profile
- Tafasitamab: Incyte
Tafasitamab (MOR208) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. Tafasitamab (MOR208, formerly Xmab®5574) is an investigational monoclonal antibody directed against the antigen CD19 which is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL). Tafasitamab (MOR208) binds to CD19. This antigen is broadly and homogeneously expressed across different B cell malignancies including diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CD19 is able to enhance B cell receptor (BCR) signaling, which is important for B cell survival. Therefore, CD19 is considered a potential therapeutic target for drugs aimed at treating B cell-related lymphomas and leukemias. Currently the product is in Phase III stage of development for the treatment of Malt Lymphoma.
Dive deep into rich insights for drugs for Malt Lymphoma Market Drivers and Malt Lymphoma Market Barriers, click here @ Malt Lymphoma Unmet Needs and Analyst Views
Malt Lymphoma Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Malt Lymphoma. The companies which have their Malt Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Incyte.
Scope of the Malt Lymphoma Pipeline Report
- Coverage- Global
- Malt Lymphoma Companies- MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology, and Others.
- Malt Lymphoma Pipeline Therapies- Zanubrutinib, Lenalidomide, Obinutuzumab, tafasitamab, Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide, Fentanyl sublingual spray, Fragmin, and others.
- Malt Lymphoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Malt Lymphoma Mergers and acquisitions, Malt Lymphoma Licensing Activities @ Malt Lymphoma Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Executive Summary
- Malt Lymphoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Malt Lymphoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Tafasitamab: Incyte
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Mosunetuzumab: Genentech
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- BGB-10188: BeiGene
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- PSB202: Sound Biologics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Malt Lymphoma Key Companies
- Malt Lymphoma Key Products
- Malt Lymphoma – Unmet Needs
- Malt Lymphoma – Market Drivers and Barriers
- Malt Lymphoma – Future Perspectives and Conclusion
- Malt Lymphoma Analyst Views
- Malt Lymphoma Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
